Eton Pharmaceuticals (ETON) Non-Current Debt (2019 - 2026)

Eton Pharmaceuticals has disclosed Non-Current Debt across 8 years of filings, most recently posting $19.1 million for Q2 2026.

• In Q2 2026, Non-Current Debt fell 30.4% year-over-year to $19.1 million; the TTM figure through Jun 2026 stood at $19.1 million (down 30.4% YoY), while the FY2025 annual figure was $21.8 million, down 26.98% from the prior year.
• Non-Current Debt came in at $19.1 million for Q2 2026 at Eton Pharmaceuticals, down from $21.8 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $30.0 million in Q1 2025 to a low of $4.2 million in Q3 2023.
• Average Non-Current Debt over 5 years is $14.8 million, with a median of $6.3 million recorded in 2022.
• Year-over-year, Non-Current Debt increased 2.39% in 2022 and slumped 30.4% in 2026.
• Over 5 years, Non-Current Debt stood at $5.4 million in 2022, then declined by 22.05% to $4.2 million in 2023, then surged by 610.29% to $29.8 million in 2024, then slipped by 26.98% to $21.8 million in 2025, then decreased by 12.36% to $19.1 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $19.1 million in Q2 2026, $21.8 million in Q4 2025, and $27.6 million in Q3 2025.